Evidence map›Paper›PMID 40244269›Full record

ArticleInternational journal of molecular sciences2025

FDX1 Regulates the Phosphorylation of ATM, DNA-PKcs Akt, and EGFR and Affects Radioresistance Under Severe Hypoxia in the Glioblastoma Cell Line T98G.

Takuma Hashimoto, Kazuki Tsubota, Khaled Hatabi, Yoshio Hosoi

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Role of Ferredoxin 1Cancer pathogenesis and therapy · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Takuma HashimotoLaboratory of Radiation Biology, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.ORCID 0000-0002-8762-6027
Kazuki TsubotaLaboratory of Radiation Biology, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.
Khaled HatabiLaboratory of Radiation Biology, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.ORCID 0000-0002-8845-4562
Yoshio HosoiLaboratory of Radiation Biology, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.ORCID 0000-0003-3434-594X

Funding

The Ministry of Education, Culture, Sports, Science and Technology (MEXT) Japan Grants-in-Aid for Scientific Research #20H03616
6 · The paper itself

Abstract

Hypoxic cells exhibit radioresistance, which is associated with poor prognosis in cancer patients. Understanding the molecular mechanisms underlying radioresistance in hypoxic tumor cells is crucial for improving radiotherapy efficacy. In this study, we examined the role of FDX1 in regulating cellular responses to severe hypoxia in glioblastoma cell lines T98G and A172. We found that FDX1 expression was upregulated under severe hypoxia, and its knockdown reduced the hypoxia-induced activation of key radioresistance factors and cellular survival mechanisms, including ATM, DNA-PKcs, Akt, and EGFR. FDX1 knockdown also sensitized T98G cells to radiation under severe hypoxia. Furthermore, FDX1 was found to regulate HIF-1α protein level, while HIF-1α did not regulate FDX1 expression. These results suggest that FDX1 may be a novel therapeutic target to overcome radioresistance in glioblastoma under severe hypoxia.

Indexed as

Ataxia Telangiectasia Mutated ProteinsDNA-Activated Protein KinaseErbB ReceptorsGlioblastomaProto-Oncogene Proteins c-aktRadiation ToleranceCell HypoxiaCell Line, TumorGene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1, alpha SubunitPhosphorylationAtaxia Telangiectasia Mutated ProteinsATM protein, humanDNA-Activated Protein KinaseEGFR protein, humanErbB ReceptorsHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitPRKDC protein, humanProto-Oncogene Proteins c-aktAktATMDNA-PKcsEGFRFDX1hypoxiaradiation sensitivity

Identifiers

PMID40244269
PMCPMC11990063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.